1. Home
  2. PCRX vs SPTX Comparison

PCRX vs SPTX Comparison

Compare PCRX & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$25.17

Market Cap

999.0M

Sector

Health Care

ML Signal

HOLD

Logo Seaport Therapeutics Inc. Common Stock

SPTX

Seaport Therapeutics Inc. Common Stock

N/A

Current Price

$21.25

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PCRX
SPTX
Founded
2006
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
999.0M
1.1B
IPO Year
2010
2026

Fundamental Metrics

Financial Performance
Metric
PCRX
SPTX
Price
$25.17
$21.25
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$30.25
N/A
AVG Volume (30 Days)
450.1K
206.6K
Earning Date
04-30-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
107.44
N/A
EPS
0.07
N/A
Revenue
$541,533,000.00
N/A
Revenue This Year
$6.78
N/A
Revenue Next Year
$8.54
N/A
P/E Ratio
$364.29
N/A
Revenue Growth
26.04
N/A
52 Week Low
$18.80
$17.59
52 Week High
$27.64
$22.98

Technical Indicators

Market Signals
Indicator
PCRX
SPTX
Relative Strength Index (RSI) 60.53 62.35
Support Level $22.03 $17.89
Resistance Level $27.03 $21.59
Average True Range (ATR) 0.94 1.88
MACD 0.12 0.06
Stochastic Oscillator 69.42 68.80

Price Performance

Historical Comparison
PCRX
SPTX

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About SPTX Seaport Therapeutics Inc. Common Stock

Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.

Share on Social Networks: